The introduction of highly effective direct-acting antivirals has transformed the HCV treatment landscape, enabling cure ...

Adults aged 18 to 49 years at increased risk for RSV-associated lower respiratory tract disease are now eligible for the ...

March 13 (Reuters) - British drugmaker GSK said on Friday the U.S. Food and Drug Administration has expanded the approved age range for its respiratory syncytial virus vaccine, Arexvy, to include ...

The FDA has approved GSK's Arexvy for adults aged 18 to 49 who have increased risk of complications from the virus.

On Friday, the U.S. Food and Drug Administration (FDA) expanded the approved age indication for GSK plc’s GSK respiratory ...

In outpatient care, RSV infections in children younger than 2 years present with distinct clinical features and greater ...

We’re still in the early stages of RSV season, but doctors are already worried about a rise in cases. As we head into the peak of 2025 RSV season, parents are once again facing an uptick in cases, ...

Flu cases are “very high” across much of Idaho, federal health experts say, and another respiratory virus is on the rise as ...

The American College of Physicians (ACP) issued updated vaccine practice points for physicians that advise adults aged 75 or ...

Despite being severely affected by the virus, Laine Lewis from Hucclecote near Gloucester said Malachi, now 12, is defying ...

Among older adults, a respiratory syncytial virus (RSV) infection increases the risk of cardiovascular events over the following year, according to new Danish data. Researchers say its effect on CV ...

"We found that residents of these facilities suffered significantly greater morbidity and mortality from RSV infections compared with older adults living in the community." — Brenda L. Tesini, MD, ...